Why blood-based biomarkers allow for effective use of innovative DMTs in the future?

Prof Henrik Zetterberg, Sweden

Research and DiagnosticsBiomarkers

 

Why blood-based biomarkers allow for effective use of innovative DMTs in the future?

 

Prof Henrik Zetterberg, Sweden

March 24, 2022

 

 

At ADPD 2022, Professor Henrik Zetterberg explains why he's pioneering research into blood-based biomarkers for Alzheimer's disease to allow for the effective use of innovative disease-modifying treatments in the future.

 

 

© 2024 F. Hoffmann-La Roche Ltd. M-XX-00016029 Date of preparation: January 2024

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

I am a healthcare professional

Not a healthcare professional? Browse:

Roche's patients website Roche.com

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically